帕博利珠单抗治疗既往经治的微卫星高度不稳定/错配修复缺陷晚期结直肠癌:KEYNOTE-164最终分析
KEYNOTE-164 2期研究最终分析纳入不可切除或转移性MSI-H/dMMR结直肠癌患者,A组(≥2线治疗)61例、B组(≥1线治疗)63例,接受帕博利珠单抗200 mg每3周一次、最多35个周期。A组ORR 32.8%(95%CI 21.3%-46.0%)、B组34.9%(95%CI 23.3%-48.0%),中位OS分别为31.4个月和47.0个月,未观察到新的安全性信号。
要点
- A组ORR 32.8%(95%CI 21.3%-46.0%),B组ORR 34.9%(95%CI 23.3%-48.0%)
- 两组中位缓解持续时间均未达到;A组中位PFS 2.3个月,B组4.1个月
- A组中位OS 31.4个月(95%CI 21.4-58.0),B组47.0个月(95%CI 19.2-未达到)
核心结论
- 帕博利珠单抗在既往经治的MSI-H/dMMR晚期结直肠癌患者中持续显示持久的抗肿瘤活性、延长的OS和可控的安全性。
研究设计与样本
- 2期KEYNOTE-164研究最终分析,纳入不可切除或转移性MSI-H/dMMR结直肠癌患者。
- A组为既往接受≥2种全身治疗者61例,B组为既往接受≥1种全身治疗者63例。
- 患者接受帕博利珠单抗200 mg静脉给药每3周一次、最多35个周期。
- 主要终点为盲法独立中心审查按RECIST 1.1评估的客观缓解率(ORR)。
主要发现
- A组中位随访62.2个月,B组中位随访54.4个月。
- A组ORR 32.8%(95%CI 21.3%-46.0%),B组ORR 34.9%(95%CI 23.3%-48.0%)。
- 两组中位缓解持续时间(DOR)均未达到。
- A组中位PFS 2.3个月(95%CI 2.1-8.1),B组中位PFS 4.1个月(95%CI 2.1-18.9)。
- A组中位OS 31.4个月(95%CI 21.4-58.0),B组中位OS 47.0个月(95%CI 19.2-未达到);未观察到新的安全性信号。
关键数值与推荐
- 客观缓解率:A组32.8%(95%CI 21.3%-46.0%),B组34.9%(95%CI 23.3%-48.0%)。
- 中位无进展生存期:A组2.3个月(95%CI 2.1-8.1),B组4.1个月(95%CI 2.1-18.9)。
- 中位总生存期:A组31.4个月(95%CI 21.4-58.0),B组47.0个月(95%CI 19.2-未达到)。
- 中位缓解持续时间:两组均未达到。
临床怎么用
- 帕博利珠单抗200 mg静脉给药每3周一次、最多35个周期用于既往经治的MSI-H/dMMR晚期结直肠癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pembrolizumab demonstrated durable clinical benefit and manageable safety in previously treated advanced or metastatic microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer (CRC) in the phase 2 KEYNOTE-164 study. Results from the final analysis are presented. METHODS: Eligible patients had unresectable or metastatic MSI-H/dMMR CRC and ≥2 prior systemic therapies (cohort A) or ≥1 prior systemic therapy (cohort B). Patients received pembrolizumab 200 mg intravenously every 3 weeks for ≤35 cycles. The primary end-point was objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors, version 1.1 by blinded independent central review. Secondary end-points included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety and tolerability. RESULTS: Sixty-one patients in cohort A and 63 patients in cohort B were enroled; median follow-up was 62.2 months and 54.4 months, respectively. ORR was 32.8% (95% CI, 21.3%-46.0%) in cohort A and 34.9% (95% CI, 23.3%-48.0%) in cohort B. Median DOR was not reached (NR) in either cohort. Median PFS was 2.3 months (95% CI, 2.1-8.1) in cohort A and 4.1 months (95% CI, 2.1-18.9) in cohort B. Median OS was 31.4 months (95% CI, 21.4-58.0) in cohort A and 47.0 months (95% CI, 19.2-NR) in cohort B. No new safety signals were observed. Nine patients who initially responded experienced disease progression off therapy and received second-course pembrolizumab. Six patients (66.7%) completed an additional 17 cycles of pembrolizumab, and 2 patients achieved a partial response. CONCLUSIONS: Pembrolizumab continued to show durable antitumor activity, prolonged OS, and manageable safety in patients with previously treated MSI-H/dMMR CRC. CLINICAL TRIAL REGISTRY INFORMATION: ClinicalTrials.gov, NCT02460198.
引用
- Le DT, Diaz LA, Kim TW, et al. Pembrolizumab for previously treated, microsatellite instability-high/mismatch repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164. Eur J Cancer. 2023. PMID: 37141828. doi:10.1016/j.ejca.2023.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。